Advertisement

Kim Chi, MD

Articles

Dr. Chi on Future Research Efforts With PARP Inhibitors in Metastatic Prostate Cancer

October 1st 2021

Kim Chi, MD, discusses future research directions with PARP inhibitors in metastatic prostate cancer.

Dr. Chi on the Design of the AMPLITUDE Trial in mCSPC

September 28th 2021

Kim Chi, MD, discusses the design of the phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Dr. Chi on the Utility of Liquid Biopsy in Prostate Cancer

June 26th 2020

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

Dr. Chi on the Rationale for the PC-BETS Study With ctDNA in Prostate Cancer

June 16th 2020

Kim Chi, MD, senior research scientist, Vancouver Prostate Centre, discusses clinical challenges in prostate cancer.

Dr. Chi on the Prostate Cancer Biomarker Enrichment and Treatment Selection Study

June 4th 2020

Kim Chi, MD, discusses prostate cancer biomarker enrichment and treatment selection study.

Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

August 1st 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Chi Discusses the LATITUDE Study in Metastatic Prostate Cancer

July 25th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.

Dr. Chi on Combinations with Androgen Deprivation Therapy for Prostate Cancer

July 7th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Dr. Chi on Androgen Deprivation Therapy for High-Risk Metastatic Hormone-Naive Prostate Cancer

June 20th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses androgen deprivation therapy (ADT) with abiraterone acetate (Zytiga) plus prednisone or placebo in patients with high-risk metastatic hormone-naïve prostate cancer.

Advertisement
Advertisement